Vistagen Therapeutics, Inc. (VTGN)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
0.61 USD
-0.02
(-3.027%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:51 p.m. EDT
Despite a technically stabilizing price action near support, VTGN is a catastrophic long-term hold with zero dividend yield and severe fundamental deterioration (negative growth, massive operating losses, and pending class action litigation). The options chain reveals a 'trapped capital' scenario where speculators are drowning in long-term deep OTM puts, suggesting they are betting on a total wipeout rather than a standard recovery. Buy now. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.106729 |
| AutoETS | 0.106732 |
| MSTL | 0.183728 |
| AutoTheta | 0.851553 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.352 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.802 |
| Revenue per Share | 0.022 |
| Market Cap | 24,116,886 |
| Forward P/E | -0.54 |
| Beta | 0.33 |
| Website | https://www.vistagen.com |
As of April 18, 2026, 11:51 p.m. EDT: Options sentiment is heavily skewed towards downside protection and hedging rather than bullish speculation. While Call Open Interest builds at OTM strikes (1.0 and 2.0) for May/April, there is a very significant accumulation of Put Open Interest at deep OTM strikes ($3.00) for August 2026. This $3.00 put positioning represents a massive speculative bet on a highly improbable, massive crash (approx. 8x downside) or is reflective of a 'black swan' event anticipation given the recent litigation news. However, the dominant short-term signal comes from the May expiration: In-the-Money (ITM) Put volume and OI are significantly higher than Call volume, with $1.00 ITM puts showing superior positioning. This indicates speculators are positioning for a correction rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.702439 |
| Address1 | 343 Allerton Avenue |
| All Time High | 1,890.0 |
| All Time Low | 0.43 |
| Ask | 0.6406 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 679,090 |
| Average Daily Volume3 Month | 759,527 |
| Average Volume | 759,527 |
| Average Volume10Days | 679,090 |
| Beta | 0.328 |
| Bid | 0.5777 |
| Bid Size | 1 |
| Book Value | 1.285 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6087 |
| Current Ratio | 4.675 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.635 |
| Day Low | 0.6029 |
| Debt To Equity | 2.802 |
| Display Name | Vistagen Therapeutics |
| Earnings Call Timestamp End | 1,770,933,600 |
| Earnings Call Timestamp Start | 1,770,933,600 |
| Earnings Timestamp | 1,770,930,000 |
| Earnings Timestamp End | 1,770,930,000 |
| Earnings Timestamp Start | 1,770,930,000 |
| Ebitda | -69,717,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.52 |
| Enterprise To Revenue | -45.914 |
| Enterprise Value | -36,226,112 |
| Eps Current Year | -1.71333 |
| Eps Forward | -1.1325 |
| Eps Trailing Twelve Months | -1.9 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.5872 |
| Fifty Day Average Change | 0.021499991 |
| Fifty Day Average Change Percent | 0.03661443 |
| Fifty Two Week Change Percent | -70.243904 |
| Fifty Two Week High | 5.14 |
| Fifty Two Week High Change | -4.5313 |
| Fifty Two Week High Change Percent | -0.8815759 |
| Fifty Two Week Low | 0.43 |
| Fifty Two Week Low Change | 0.17869997 |
| Fifty Two Week Low Change Percent | 0.41558132 |
| Fifty Two Week Range | 0.43 - 5.14 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,308,663,000,000 |
| Float Shares | 33,777,509 |
| Forward Eps | -1.1325 |
| Forward P E | -0.5374834 |
| Free Cashflow | -36,167,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 59 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 789,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0026800002 |
| Held Percent Institutions | 0.38247 |
| Implied Shares Outstanding | 39,620,317 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,743,379,200 |
| Last Split Date | 1,686,096,000 |
| Last Split Factor | 1:30 |
| Long Business Summary | Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. |
| Long Name | Vistagen Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 24,116,886 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_7691787 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -67,046,000 |
| Next Fiscal Year End | 1,774,915,200 |
| Non Diluted Market Cap | 24,116,886 |
| Number Of Analyst Opinions | 3 |
| Open | 0.6277 |
| Operating Cashflow | -60,298,000 |
| Operating Margins | -64.508255 |
| Payout Ratio | 0.0 |
| Phone | 650 577 3600 |
| Pre Market Change | 0.011400044 |
| Pre Market Change Percent | 1.872851 |
| Pre Market Price | 0.6201 |
| Pre Market Time | 1,776,775,411 |
| Previous Close | 0.6277 |
| Price Eps Current Year | -0.35527304 |
| Price Hint | 4 |
| Price To Book | 0.4736965 |
| Price To Sales Trailing12 Months | 30.566395 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.566 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.019 |
| Regular Market Change Percent | -3.02692 |
| Regular Market Day High | 0.635 |
| Regular Market Day Low | 0.6029 |
| Regular Market Day Range | 0.6029 - 0.635 |
| Regular Market Open | 0.6277 |
| Regular Market Previous Close | 0.6277 |
| Regular Market Price | 0.6087 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 598,866 |
| Return On Assets | -0.55527997 |
| Return On Equity | -1.01553 |
| Revenue Growth | 0.295 |
| Revenue Per Share | 0.022 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 39,620,317 |
| Shares Percent Shares Out | 0.0356 |
| Shares Short | 1,410,489 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,519,296 |
| Short Name | VistaGen Therapeutics, Inc. |
| Short Percent Of Float | 0.0508 |
| Short Ratio | 3.02 |
| Source Interval | 15 |
| State | CA |
| Symbol | VTGN |
| Target High Price | 1.0 |
| Target Low Price | 0.9 |
| Target Mean Price | 0.96667 |
| Target Median Price | 1.0 |
| Total Cash | 61,770,000 |
| Total Cash Per Share | 1.559 |
| Total Debt | 1,427,000 |
| Total Revenue | 789,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.31515 |
| Two Hundred Day Average Change | -1.70645 |
| Two Hundred Day Average Change Percent | -0.7370797 |
| Type Disp | Equity |
| Volume | 598,866 |
| Website | https://www.vistagen.com |
| Zip | 94,080 |